CN106177054A - A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae - Google Patents
A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae Download PDFInfo
- Publication number
- CN106177054A CN106177054A CN201510214672.7A CN201510214672A CN106177054A CN 106177054 A CN106177054 A CN 106177054A CN 201510214672 A CN201510214672 A CN 201510214672A CN 106177054 A CN106177054 A CN 106177054A
- Authority
- CN
- China
- Prior art keywords
- health composition
- radix
- pericarpium citri
- citri reticulatae
- cortex mori
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 230000036541 health Effects 0.000 title claims abstract description 46
- 230000003345 hyperglycaemic effect Effects 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 33
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 241000233779 Cyclocarya paliurus Species 0.000 claims abstract description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 7
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 6
- 241000208340 Araliaceae Species 0.000 claims abstract description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 5
- 235000008434 ginseng Nutrition 0.000 claims abstract description 5
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 5
- 210000004369 blood Anatomy 0.000 claims description 69
- 239000008280 blood Substances 0.000 claims description 69
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 240000000588 Hericium erinaceus Species 0.000 claims description 3
- 235000007328 Hericium erinaceus Nutrition 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 241001506047 Tremella Species 0.000 claims description 3
- 244000309464 bull Species 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 235000011201 Ginkgo Nutrition 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 claims description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 2
- 239000009636 Huang Qi Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 241000180649 Panax notoginseng Species 0.000 claims description 2
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- -1 hydroxypropyl methyl Chemical group 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 241001116389 Aloe Species 0.000 claims 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims 1
- 235000017491 Bambusa tulda Nutrition 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 244000082204 Phyllostachys viridis Species 0.000 claims 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000011399 aloe vera Nutrition 0.000 claims 1
- 239000011425 bamboo Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 206010020772 Hypertension Diseases 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 31
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 26
- 239000008103 glucose Substances 0.000 description 26
- 206010012601 diabetes mellitus Diseases 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 235000000346 sugar Nutrition 0.000 description 19
- 230000036772 blood pressure Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 235000013305 food Nutrition 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 6
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 201000005577 familial hyperlipidemia Diseases 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 3
- 235000008708 Morus alba Nutrition 0.000 description 3
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000282894 Sus scrofa domesticus Species 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 235000014590 basal diet Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008354 sodium chloride injection Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 101000637031 Homo sapiens Trafficking protein particle complex subunit 9 Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 102100031926 Trafficking protein particle complex subunit 9 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- SLYRGJDSFOCAAI-UHFFFAOYSA-N 1,3-thiazolidin-2-one Chemical compound O=C1NCCS1 SLYRGJDSFOCAAI-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000027796 Blood pressure disease Diseases 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010051244 Dyschezia Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000011279 abdominal lump Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical class CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Abstract
The invention discloses a kind of containing Cortex Mori with the health composition of Pericarpium Citri Reticulatae, wherein the percentage by weight of the two can be Cortex Mori and the Pericarpium Citri Reticulatae of 1-99% of 1-99%.Described health composition can also comprise the one in Rhizoma Polygonati Odorati, Rhizoma Dioscoreae, Radix Puerariae, Poria, leaf of Cyclocarya paliurus Iljinskaja, Fructus Lycii, Radix Ginseng, Herba Dendrobii, Radix Angelicae Sinensis, Radix Rhodiolae or its combination in any.Present invention also offers the application in terms of preparation auxiliary treatment hyperglycemia, hypertension or hyperlipidemia health composition of the described health composition.The health composition of the present invention, based on natural drug, has no side effect, and has clear curative effect, synergism and substantially and is prone to the advantages such as masses take.
Description
Technical field
The invention belongs to field of health care food, be specifically related to a kind of blood sugar lowering comprising Cortex Mori and Pericarpium Citri Reticulatae and protect
It is good for compositions and preparation thereof and purposes.
Background technology
Diabetes (diabetes mellitus, DM) be a kind of common multi-pathogenesis have the interior of genetic predisposition
Secretion metabolism disorder disease, along with growth in the living standard, its sickness rate in the trend risen year by year,
Becoming the 3rd killer being detrimental to health after cancer, cardiovascular and cerebrovascular disease, diabetes are with hyperglycemia
For outstanding feature, and cause series of clinical manifestations.The relevant diabetes that China completes for 1997 are popular
Sick investigation problem of learning show, and national onset diabetes rate rises to 3.2%, more from 1% in 1980
Seriously in the old people of more than 60 years old the sickness rate of diabetes more than 11%.Up-to-date in 2012 grinds
Studying carefully report display, China diabetes patient occupies the whole world first.
" quenching one's thirst " or " diseases due to endogenous heat of ZANG FU organs " category of the diabetes spp traditional Chinese medical science.Diabetes are broadly divided into by modern medicine
Two types a: class is the insulin-dependent (TDDM) of I type, based on inherited genetic factors, mostly occurs
In teenager.The another kind of non-insulin-depending type for II type (NIDDM), because of insulin resistant and pancreas
Island element secretion relative deficiency or delay, cause blood glucose to raise, and course of disease elder may occur in which the complication of diabetes,
It is mainly in and grows up or middle-aged and elderly people.In all diabeticss, 90% is above suffering from type ii diabetes.
At present, the treatment of diabetes is except with going back some orally-taken blood sugar reducing medicines of adapted in addition to insulin, such as: sulfonylurea,
Metformin class, alpha-glucosidase inhibitor, thiazolidone etc..Although western medicine effect comparison is bright
Aobvious, but side effect is big, as easily caused hypoglycemia, lactic acidosis, intestinal discomfort etc..This disease such as can not get
Control, it will cause severe chronic complication and then disable lethal.Therefore, the preventing and treating strengthening diabetes is arranged
Executing and paid attention to by countries in the world, research prevents and treats the newtype drug of diabetes and health food is domestic and international
The advanced subject of association area.Non-medication treatment diabetes have become current medical science, threpsology, food
One of focus of scientific research.Although the enterprise that lot of domestic and international is big and scientific research institution, fall over each other research and open
Send out hypoglycemic medicine or substitute products, but mostly the most all because of expensive, carrier is undesirable, effect is unstable
Or take trouble and not by people's recognition and acceptance.
Additionally, hypertension, hyperlipidemia are also puzzlements people " modern civilization diseases " in recent years, to human body
Healthy is very harmful, similar with diabetes to its difficulty prevented and treated.
Hypertension (hypertension) is a kind of with the abnormal cardiovascular disease rising a height of principal character of arterial pressure
Sick.The cause of disease is divided into essential hypertension and secondary hypertension.The former accounts for the 90% of hypertension, is referred to as height
Blood pressure diseases.Primary disease belongs to the categories such as " dizziness ", " headache " of the traditional Chinese medical science.
Hyperlipemia (hyperlipemia) also known as hyperlipoproteinemia, can behave as hypercholesterolemia,
Hypertriglyceridemia or both have concurrently, it is with tremulous pulse medicated porridge sample hardening, diabetes, fatty liver, nephropathy
The closest etc. relation.Consequence is especially had day by day to cause people in the morbidity of cardiovascular and cerebrovascular disease
Attention.The traditional Chinese medical science thinks that hyperlipemia belongs to the categories such as " turbid resistance ", " phlegm-damp ", " fat ", " damp and hot ".
Hyperglycemia, hypertension, hyperlipidemia (" three high ") cause of disease are complicated, and the current cause of disease is the clearest and the most definite.
Although the comparitive study of western medical treatment is certainly at present, but is combined the treatment difficulty of disease and complication thereof relatively
Greatly, can cause the side effect that degree is different, patient is often difficult to stand simultaneously, it is impossible to adhere to treatment.In
Cure the understanding to above-mentioned disease and preventing and treating, be then to start with from entirety conditioning, determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, although do not have
Western medicine is quick, but is nursed one's health by entirety, and symptom and index all can be effectively controlled, simultaneously can be effective
Protection target organ etc..From clinically, hyperlipidemia, hyperglycemia, hypertensive patients occur, mutually often
For cause and effect.Recently, more result of study confirms, in order to reach to prevent and delay complication to occur and send out
The purpose of exhibition, it should extremely emphasize the control of many factors, such as in type ii diabetes, except strictly
Control, outside blood glucose, blood pressure level, also to take strictly to control blood lipid level, strictly control body weight,
The measures such as conventional anticoagulant therapy, to reduce the risk of macroangiopathy further.But so far can be same
Time prevention or the Chinese medicine composition for the treatment of " three high " know clearly very few, it is possible to obtain satisfied curative effect and patient
The pharmaceutical composition that compliance is high rarely has report especially, and therefore, research and development can prevent simultaneously and treat
The safely and effectively medicine of " three high ", is the task of top priority, extremely urgent.
In the last few years, from natural product, the new composition having physiologically active or lead compound are found to open
Send out new drug or health food base section has become the focus of global concern and research.Seek blood sugar lowering, blood pressure lowering and fall
Its functional factor is also dissected, and then Development and Production goes out blood sugar lowering, blood pressure lowering, fall by fat food resource
The Material for Health Food of blood fat food is expected to become the good approach treating these diseases.
Cortex Mori is the dry root bark of moraceae plants Mulberry (Morus alba L.).Another name Cortex Mori, Mulberry
Root bark, Cortex Mori, Morus alba skin.Main product in Anhui, Henan, Zhejiang, Jiangsu, the ground such as Hunan.Autumn end falls
Leaf excavates root before the secondary spring germinates, and scrapes off yellowish-brown rough bark, longitudinally cuts open, strips root bark, dry.
Cortex Mori has eliminating pathogen from the lung for relieving asthma, effect of inducing diuresis to remove edema, can be used for lung-heat cough with asthma, the edema of the face, urine
Unfavorable disease such as grade.Modern pharmacology research show Cortex Mori have blood pressure lowering, diuresis, sedation and analgesia, antiinflammatory,
Antibacterial and blood sugar lowering isoreactivity.
Pericarpium Citri Reticulatae is being dried to of rutaceae orange (Citrus reticulata Blanco) and variety thereof
Ripe peel, medical material is divided into " Pericarpium Citri Reticulatae " and " Pericarpium citri reticuatae chachiensis ".Harvesting ripe fruit, strips peel, dries or low
Temperature is dried.Main product is in China Jiangxi, Hunan, Guizhou, Yunnan, Sichuan and other places.Bitter in the mouth, pungent, warm in nature；
Return spleen, lung meridian.There is effect of invigorating the spleen and regulating the stomach, promoting the circulation of QI to alleviate the stagnation in middle-JIAO, lowering the adverse-rising QI and eliminating phlegm.Cure mainly stagnation of QI in spleen and stomach,
The diseases such as gastral cavity abdomen covers with, nausea and vomiting, inappetence, cough with copious phlegm, and chest and diaphragm is full vexed, globus hystericus.
Although producing at present and there is the medicine of function of polysaccharide and substitute products are of a great variety, but have fall blood concurrently
The health product mainly comprising Cortex Mori and Pericarpium Citri Reticulatae of sugar, blood pressure lowering and hypolipemic function are not reported so far.
Summary of the invention
The present inventor, through long-term research and practice, obtains one unexpectedly and has blood sugar lowering, fall blood concurrently
Pressure and hypolipemic function, comprise the health composition of Cortex Mori and Pericarpium Citri Reticulatae, thus overcome in prior art
The drawbacks described above existed.
It is an object of the present invention to provide a kind of health composition comprising Cortex Mori and Pericarpium Citri Reticulatae, wherein
The percentage by weight of the two is Cortex Mori and the Pericarpium Citri Reticulatae of 1-99% of 1-99%.
In one embodiment of the invention, the percentage by weight of Cortex Mori and Pericarpium Citri Reticulatae is 20-80%'s
Cortex Mori and the Pericarpium Citri Reticulatae of 20-80%.
Preferably, the percentage by weight of Cortex Mori and Pericarpium Citri Reticulatae can be Cortex Mori and the 30-70% of 30-70%
Pericarpium Citri Reticulatae.
It is further preferred that the percentage by weight of Cortex Mori and Pericarpium Citri Reticulatae can be 40-60% Cortex Mori and
The Pericarpium Citri Reticulatae of 40-60%.
In another embodiment of the present invention, described health composition can also comprise Radix Scrophulariae, life
One in Radix Rehmanniae, leaf of Cyclocarya paliurus Iljinskaja, Radix Panacis Quinquefolii, Radix et Rhizoma Rhei (processed) or its combination in any, described Cortex Mori, old
Skin can be 1-98%:1-98% with the percentage by weight of one of above-mentioned Chinese medicine of the five flavours or its combination in any:
1-98%.
Preferably, Cortex Mori, Pericarpium Citri Reticulatae and one of above-mentioned Chinese medicine of the five flavours or the percentage by weight of its combination in any
Can be 20-60%: 20-60%: 20-60%.
In yet another embodiment of the present invention, described health composition can also comprise Fructus Lycii,
One in Radix Ginseng, Herba Dendrobii, Radix Angelicae Sinensis, Radix Rhodiolae Chinese medicine of the five flavours or its combination in any, described Chinese medicine of the five flavours
One of or the percentage by weight shared in health composition of the present invention of its combination in any can be
10-40%, preferably 20-30%, more preferably 25%.
In yet another embodiment of the present invention, above-mentioned health composition also can comprise choosing the most yellow
Essence, Thallus Laminariae (Thallus Eckloniae), Fructus Mume, Radix Notoginseng, Rhizoma Polygonati Odorati, Rhizoma Dioscoreae, Radix Puerariae, Poria, Fructus Ligustri Lucidi, Fructus Corni, Rhizoma Chuanxiong,
Rhizoma Atractylodis, Radix Scrophulariae, Radix Rehmanniae, the Radix Paeoniae Alba, Aloe, Fructus Schisandrae Chinensis, Radix Ophiopogonis, the Rhizoma Anemarrhenae, Fructus Tribuli, Folium Ginkgo,
The Radix Astragali, Herb Gynostemmae Pentaphylli, Fructus Momordicae charantiae, Radix Et Rhizoma Fagopyri Tatarici, Fructus Cucurbitae moschatae, Rhizoma amorphophalli, Herba Apii graveolentis, Stigma Maydis, Tremella, Hericium erinaceus (Bull. Ex Fr.) Pers.
One or more of in the group formed with Bulbus Allii.
In the present invention, described health composition can be carried out by the preparation method of any routine in this area
Preparation.
Further object is that providing described health composition treats high blood in preparation auxiliary
Application in terms of sugar, hypertension or hyperlipidemia health composition.
A further object of the present invention there are provided a kind of pharmaceutical preparation containing described health composition.
The health composition of the present invention can be prepared as any with pharmaceutically acceptable adjuvant as required
Suitably oral formulations is for blood sugar lowering, blood pressure lowering or the treatment of blood fat reducing.
In yet other embodiments, described oral formulations can be tablet, capsule,
The dosage forms such as granule, powder, effervescent, bagged steeping drug.
In yet other embodiments, described pharmaceutically acceptable adjuvant such as can select
From pregelatinized Starch, beta-schardinger dextrin-, carbomer, microcrystalline Cellulose, hydroxypropyl methyl cellulose, low take
For hydroxypropyl cellulose, Polyethylene Glycol (PEG), sodium carboxymethyl cellulose, methylcellulose, ethyl
Cellulose, mannitol, cross-linking sodium carboxymethyl cellulose, lactose, polyvinylpyrrolidone (PVP),
One in magnesium stearate, Pulvis Talci, micropowder silica gel, aspartame, sodium bicarbonate, sodium carbonate or more
Multiple.
Effect activity of each primary raw material medicine in the present invention
Cortex Mori: eliminating pathogen from the lung for relieving asthma, inducing diuresis to remove edema, can be used for lung-heat cough with asthma, the edema of the face, dysuria
Deng disease.There is blood pressure lowering, diuresis, sedation and analgesia, antiinflammatory, antibacterial and blood sugar lowering isoreactivity.
Pericarpium Citri Reticulatae: bitter in the mouth, pungent, warm in nature；Return lung, spleen channel；There is regulating qi-flowing for strengthening spleen, effect of drying dampness to eliminate phlegm,
For diseases such as distension and fullness in the abdomen, lack of appetite and vomiting, cough with copious phlegm.
Radix Scrophulariae: sweet, bitter, salty, is slightly cold；Return lung, stomach, kidney channel；There is removing heat from blood YIN nourishing, eliminating fire and detoxication
Effect.For consumption of YIN caused by febrile disease, crimson tongue excessive thirst, maculae caused by violent heat pathogen, Tianjin hinders constipation, hectic fever due to YIN-deficiency chronic cough, conjunctival congestion,
Pharyngalgia, scrofula, diphtheria, carbuncle sore tumefacting virus.
Radix Rehmanniae: sweet, bitter, cold；GUIXIN, liver, kidney channel；Clearing away heat and promoting production of body fluid, nourishing YIN and benefiting blood；For the moon
Shooting without hitting the target heat, quench one's thirst, spit blood, epistaxis, metrorrhagia, menoxenia, frequent fetal movement, the moon hinders constipation.
Radix Panacis Quinquefolii: cool in nature, sweet in the mouth, micro-hardship；Boosting qi and nourishing yin, clearing away heat and promoting production of body fluid.For deficiency of vital energy yin deficiency, interior
Heat, cough with asthma expectorant blood, deficiency-heat is tired of tired, quenches one's thirst, and dry mouth larynx is done.
Radix et Rhizoma Rhei (processed): bitter in the mouth, cold in nature.Return stomach, spleen, large intestine, liver, pericardium channel.Have purging heat to relax the bowels it
Effect, constipation, abdominal part distension, pain with tenderness stagnant for Gastrointestinal excess heat, even hyperpyrexia,
Unconsciousness and delirium.
Fructus Lycii: sweet is flat.Return liver, kidney channel.Nourishing the liver and kidney, replenishing vital essence to improve eyesight.For syndrome of yin deficiency of liver and kidney.
The sweet flat matter of this product is moistened, and flat invigorating the liver and kidney has strengthening by means of tonics effect, all cards of all hepatic and renal YIN deficiency all can apply.
Herba Dendrobii: property slightly sweet flavor is micro-salty, cold, return stomach, kidney, lung meridian；There is reinforcing stomach reg fluid, nourishing YIN and clearing away heat
Effect, lose for cloudy impairment of body fluid, xerostomia excessive thirst, lack of appetite are retched, deficiency-heat, poor vision after being ill.
Leaf of Cyclocarya paliurus Iljinskaja: mildly bitter flavor, pungent, property is put down.Have invigorating the spleen for eliminating dampness, Clearing heat and removing obstruction of fu-organs, depressed liver-energy dispersing and QI regulating,
The effect of enriching yin and nourishing kidney, to because dysfunction of the spleen, expectorant are turbid, addiction delicious food savoury, lazy dynamic, abdominal distention food stagnation,
The liver silt stagnation of QI and the obesity that causes, have good improvement.
Radix Ginseng: property is flat, sweet in the mouth, micro-hardship, tepor.Return spleen, lung meridian.Effect: strongly invigorating primordial QI, multiple arteries and veins
Gu de-, invigorating the spleen to benefit the lung, promoting the production of body fluid to quench thirst, Fructus Alpiniae Oxyphyllae of calming the nerves.Cure mainly: impairment caused by overstrain is deficient, lack of appetite, asthenia, anti-
Stomach tell food, stool lingering diarrhea, empty cough with asthma rush, spontaneous perspiration sudden collapse, palpitation with fear, forgetful, dizziness and headache, sexual impotence,
Frequent micturition, quench one's thirst, woman uterine bleeding, children's's intermittent infantile convulsion and prolonged deficiency multiple, the card of all qi-blood-body fluid deficiencies.
Radix Angelicae Sinensis: warm in nature, sweet in the mouth is pungent.GUIXIN, liver, spleen channel.Benefiting blood and regulating blood circulation, menstruction regulating and pain relieving, moisturize cunning
Intestinal.Controlling menoxenia, amenorrhea is suffered from abdominal pain, and lump in the abdomen knot is poly-, metrorrhagia；Headache due to deficiency of blood, dizziness, flaccidity syndrome and arthralgia syndrome；Intestinal
Dry dyschezia, weight after bloody dysentery；Carbuncle skin ulcer is stolen, injury from falling down.
Radix Rhodiolae: sweet, bitter, flat.Return lung, heart channel.Benefiting QI for activating blood circulation, promotes blood circulation and relievings asthma.For deficiency of vital energy blood
The stasis of blood, obstruction of qi in the chest and cardialgia, apoplectic hemiplegia, asthenia is panted.
Technical scheme has the advantage that
Compared with prior art, the present inventor has carried out a large amount of screening in numerous Chinese medicines and food, thus
Obtain a kind of health composition comprising the Chinese medicine such as Cortex Mori and Pericarpium Citri Reticulatae, described health composition unexpectedly
Have the excellent effect of blood sugar lowering, blood pressure lowering and blood fat reducing concurrently, and in blood sugar lowering, blood pressure lowering and blood fat reducing merit
Aspect can create obvious synergism.Have clear curative effect, easy to use, synergism substantially and
It is prone to the advantages such as masses take.
The health composition of the present invention, based on natural drug, has no side effect, and makes patient at normal drink
In the case of food, consciously safeguard glucostasis, it is thus achieved that the non-drug therapy effect of diabetes.
Detailed description of the invention
To further describe the present invention below in detail.It is pointed out that following description is only to this
The illustration of the technical scheme that invention is claimed, the not any restriction to these technical schemes.This
The content that the protection domain of invention is recorded with appended claims is as the criterion.
Embodiment 1
Formula forms: Cortex Mori 1.0kg, Pericarpium Citri Reticulatae 9.0kg.
Preparation method:
2.1 accurately weigh each taste Chinese medicine according to above-mentioned formula, clean by clean water, boil extraction 2 times；
For the first time add 12 times amount water, extracts 2 hours, add 10 times amount water for the second time, extract 1 hour, 100
Mesh filters；
2.2 united extraction liquid, filter, and filtrate is concentrated into 60 DEG C of heat and surveys relative density 1.05-1.08, standby；
2.3 filtrates add formula proportion amount cycloheptaamylose, is heated to 85 DEG C, after being uniformly mixed,
Constant temperature 30 minutes,
Filtrate is added in spray dryer by 2.4, first preheating tower temperature, treats that inlet temperature reaches 210 DEG C ± 10
Charging is started after DEG C；The regulation of flow to be carried out, wind speed after charging, leaving air temp is controlled 95 DEG C ±
5 DEG C, obtain extract powder, seal powder with double-deck clean plastic bag packaging；
2.4 by formula proportion amount weigh microcrystalline Cellulose, calcium hydrogen phosphate, silicon dioxide, magnesium stearate mix
Close 3-5 minute to uniformly, obtain mixed material；
Mixed material is carried out soft material processed with 80% edible ethanol by 2.5, crosses 14 mesh, obtains wet granular；Wet
Grain is dried to moisture≤5.0%.Dry granule is crossed 16 mesh granulate, obtains dry granule；
Total mixture material is filled by every 0.3g by 2.6 with No. 1 capsule.
Embodiment 2
1, formula composition: Cortex Mori 2.0kg, Pericarpium Citri Reticulatae 7.0kg, leaf of Cyclocarya paliurus Iljinskaja 1.0kg.
2, preparation method: with embodiment 1.
Embodiment 3
1, formula composition: Cortex Mori 3.0kg, Herba Dendrobii 3.0kg, leaf of Cyclocarya paliurus Iljinskaja 3.0kg, Pericarpium Citri Reticulatae 1.0kg.
2, preparation method: with embodiment 1.
Embodiment 4
1, formula composition: Cortex Mori 5.0kg, Pericarpium Citri Reticulatae 2.0kg, Radix Scrophulariae 1.5kg, Radix Rehmanniae 0.5kg,
Radix Panacis Quinquefolii 0.5kg, Radix et Rhizoma Rhei (processed) 0.5kg.
2, preparation method: with embodiment 1.
Embodiment 5
1, formula composition: Cortex Mori 7.0kg, Pericarpium Citri Reticulatae 0.5kg, Fructus Lycii 0.5kg, Radix Ginseng 0.5kg,
Herba Dendrobii 0.5kg, Radix Angelicae Sinensis 0.5kg, Radix Rhodiolae 0.5kg.
2, preparation method: with embodiment 1.
Embodiment 6
1, formula composition: Cortex Mori 1.0kg, Pericarpium Citri Reticulatae 1.0kg, Fructus Corni 1.0kg, Hericium erinaceus (Bull. Ex Fr.) Pers. 1.0kg,
Thallus Laminariae (Thallus Eckloniae) 1.0kg, Rhizoma Polygonati 1.0kg, Rhizoma Atractylodis 1.0kg, Radix Paeoniae Alba 1.0kg, Bulbus Allii 1.0kg, Tremella 1.0kg.
2, preparation method: with embodiment 1.
Comparative example 1
Choose the sample as a comparison case 1 that Cortex Mori 10kg is prepared by the preparation method in embodiment 1.
Comparative example 2
Choose the sample as a comparison case 2 that Pericarpium Citri Reticulatae 10kg is prepared by the preparation method in embodiment 1.
Comparative example 3
Choose the sample as a comparison case 3 that Fructus Lycii 10kg is prepared by the preparation method in embodiment 1.
The scope of the present invention is not limited to above example, and each component in above-described embodiment is all selected from
Commercial goods, by the preparation process that this area is conventional, can make multiple dosage form described on pharmaceutics,
Such as capsule, granule, powder, tablet, oral liquid, teabag etc..
Experimental example 1: blood sugar lowering is tested
1, material and method
1.1 samples and reagent: sample prepared by embodiment 1-6 and comparative example 1-3, be respectively designated as S1,
S2, S3, S4, S5, S6, and D1, D2, D3；Streptozotocin, SIGMA Products,
Specification: 1g/ props up, lot number: SLBJ7785V；The sodium chloride injection (normal saline) of 0.9%, rule
Lattice: 250ml/ bottle, Kelun Pharm Ind Co., Ltd., Sichuan, lot number: C13102005-1；High lipid food
Formula (79% basal diet+1% cholesterol+15% fresh yolk+5% Adeps Sus domestica), picric acid etc..
1.2 instrument W-80A eddy mixers, Instrument Factory of Shanghai Medical Univ.'s product；Electronic balance, mettler
Toledo, made by mettler-toledo group, model: pl303；LDZ5-2 centrifuge, north
Jing Yiyonglixinjichang；Johnson & Johnson surely person of outstanding talent's blood glucose meter (Johnson & Johnson (Chinese) medical device company limited)；
BECKMAN Synchron CX5 fully automatic blood biochemistry analyzer (U.S.)；Microplate reader, bio-rad
(U.S.), model: iMark；Other: platform balance, fixing cage etc..
1.3 laboratory animal SPF level SD rats, body weight 160～180g, male, big by south medical courses in general
Experimental Animal Center provides, the quality certification number: SCXK (Guangdong) 2011-0015.Animal is in SPF level barrier
Level Animal House is raised, and animal use credit number is: SYXK (Guangdong) 2012-0081.
1.4 dosage arrange adult's plan dosage and are 3.0g/60kg BW days, and human body 10 times amount is rat
Dosage, dosage is with crude drug gauge.
1.5 statistical analysis use SPSS17.0 statistical software to carry out data process, and parameter mean ±
Standard deviationRepresenting, comparing between group and use ANOVA variance analysis test, p ＜ 0.05 is for there being statistics
Learn difference.
2. method and result
2.1 method
2.1.1 rat feed normal diet: Semen Maydis powder 80%, flour 15%, analysis for soybean powder 5%；High fat
Feedstuff: 79% basal diet+1% cholesterol+15% fresh yolk+5% Adeps Sus domestica.
2.1.2 modeling: take 160-180gSPF level SD rat 110, male, body weight 160～180g,
Adaptability takes 10 after feeding one week and is only used as Normal group, feeds with chow diet, and other respectively organizes elder generation
Feed 1 month with high lipid food, after selective examination blood lipids index is significantly raised, lumbar injection STZ 35mg/kg
(STZ is before use by the citric acid/sodium citrate buffering of 0.1mmol/LpH=4.5 for induced Diabetic model
Liquid is made into the solution of 6mg/mL, and is finished in 60min).7d after injection, docking gathers sky
Abdomen venous blood, measures blood glucose with blood glucose meter, is considered as being modeled as more than or equal to 16.7mmol/L by blood glucose value
Merit.After model stability, according to blood-fat and blood sugar height packet, it is orally administered to test medicine and control drug,
Observe indices.
2.1.3 it is grouped and is administered: preferable 100 the modeling success animals of state of choosing are according to blood glucose value and body
Weight average is even is divided into 10 groups: often group 10, i.e. type ii diabetes model control group (giving distilled water),
S1 group, S2 group, S3 group, S4 group, S5 group, S6 group, D1 group, D2 group and D3 group.Normally
The SD rat of not modeling 10 is Normal group (giving distilled water).Each group is administered orally by corresponding dosage
It is administered, is administered once daily, dosage period: 4 weeks (4W).
2.2 testing index
2.2.1 use blood glucose meter respectively measure administration before and be administered after 4W blood glucose value.
2.2.2 carbohydrate tolerance test: terminate a few days ago to detect in experiment；Carbohydrate tolerance detects: animal fasting
About 6 hours, each group gave variable concentrations given the test agent, oral administration of glucose 2.0g/kg after 15-20 minute,
Measuring to the blood glucose value of after glucose 0,0.5,2 hours, observing and nursing matched group is given with given the test agent group
The change of each time point Area under the curve of blood glucose after glucose.Area under the curve of blood glucose=1/2 × (0 hour blood
Sugar value+0.5 hours blood glucose value) × 0.5+1/2 × (2 hours blood glucose value+0.5 hours blood glucose value) × 1.5=
0.25 × (0 hours blood glucose value+4 × 0.5 hours blood glucose value+3 × 2 hours blood glucose value).
2.3 result
2.3.1 the impact on type ii diabetes rat blood sugar
From table 1, comparing with Normal group, it is notable that the front Glycemia Decline of administration respectively organizes rat blood sugar
Raise, show diabetes model modeling success.After being administered 4w, S1-S6 group blood glucose all has decline.
The impact on type ii diabetes rat blood sugar of table 1. sample
| Group | n | Blood glucose (mmol/L) before being administered | It is administered 4W blood glucose (mmol/L) |
| Normal group | 10 | 5.68±1.16 | 5.57±1.15 |
| Model control group | 10 | 17.26±3.87## | 21.85±3.77## |
| S1 group | 10 | 17.39±4.18 | 15.34±3.14* |
| S2 group | 10 | 16.71±4.43 | 15.77±3.72* |
| S3 group | 10 | 16.95±3.72 | 16.12±3.57* |
| S4 group | 10 | 17.42±4.30 | 15.63±3.25* |
| S5 group | 10 | 17.13±4.27 | 15.84±3.59* |
| S6 group | 10 | 17.16±3.91 | 16.39±4.11* |
| D1 group | 10 | 17.38±4.35 | 18.89±4.91 |
| D2 group | 10 | 17.59±3.88 | 19.63±5.18 |
| D3 group | 10 | 16.85±4.71 | 19.54±5.22 |
Note: compare with Normal group:##P ＜ 0.01；Compare with model group: * p ＜ 0.05
2.3.2 to type ii diabetes rat carbohydrate tolerance test result
From table 2, comparing with model control group, the Area under the curve of blood glucose of S1-S6 group all has decline.
Table 2. sample is to type ii diabetes rat carbohydrate tolerance test result
| Group | n | Area under the curve of blood glucose |
| Normal group | 10 | 16.13±3.67 |
| Model control group | 10 | 37.85±6.30## |
| S1 group | 10 | 25.64±5.72* |
| S2 group | 10 | 26.85±5.57* |
| S3 group | 10 | 24.10±5.06** |
| S4 group | 10 | 26.19±5.82* |
| S5 group | 10 | 26.47±6.01* |
| S6 group | 10 | 25.90±6.46* |
| D1 group | 10 | 33.15±6.52 |
| D2 group | 10 | 34.64±6.88 |
| D3 group | 10 | 34.96±6.32 |
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model control group: p is equal
More than 0.05.
3. conclusion: S1-S6 has an obvious hypoglycemic activity to diabetic model rats, and S1-S6
Compositions creates significant synergy in terms of blood sugar lowering.
Experimental example 2: lipid-lowering test
1, material and method
1.1 medicines and reagent: sample prepared by embodiment 1-6 and comparative example 1-3, be respectively designated as S1,
S2, S3, S4, S5, S6, and D1, D2, D3；The sodium chloride injection (normal saline) of 0.9%,
Specification: 250ml/ bottle, Kelun Pharm Ind Co., Ltd., Sichuan, lot number: C13102005-1；High fat is raised
Material formula (79% basal diet+1% cholesterol+15% fresh yolk+5% Adeps Sus domestica), distilled water, picric acid,
Deng.
1.2 instrument W-80A eddy mixers, Instrument Factory of Shanghai Medical Univ.'s product；Electronic balance, mettler
Toledo, made by mettler-toledo group, model: p1303；LDZ5-2 centrifuge, north
Jing Yiyonglixinjichang；BECKMAN Synchron CX5 fully automatic blood biochemistry analyzer is (beautiful
State)；Other: platform balance, fixing cage etc..
1.3 laboratory animal SPF level SD rats, body weight 160～180g, male, big by south medical courses in general
Experimental Animal Center provides, the quality certification number: SCXK (Guangdong) 2011-0015.Animal is in SPF level barrier
Level Animal House is raised, and animal use credit number is: SYXK (Guangdong) 2012-0081.
1.4 dosage arrange adult's plan dosage and are 3.0g/60kg BW days, and human body 10 times amount is rat
Dosage, dosage is with crude drug gauge.
1.5 statistical analysis use SPSS17.0 statistical software to carry out data process, and parameter mean ±
Standard deviation (x ± s) represents, comparing between group and use ANOVA variance analysis test, p ＜ 0.05 is for there being statistics
Learn difference.
2. method and result
2.1 packets take SPF level SD rat 110 with method, male, and body weight 160～180g is suitable
Answering property takes 10 after feeding one week and is only used as Normal group, feeds with chow diet；Residue gives high fat
Forage feed.Continuous nursing 4 weeks (determining that modeling is the most successful by timing blood drawing detection four items of blood lipid tests)
After, preferable 100 the modeling success animals of state of choosing uniformly are divided into 10 according to blood fat numerical value and body weight
Group: often group 10, i.e. hyperlipemia model matched group (giving distilled water), S1 group, S2 group, S3
Group, S4 group, S5 group, S6 group, D1 group, D2 group and D3 group.
High lipid food is started to be administered and continue (just feeding high lipid food by above packet situation after feeding 4 weeks
Often matched group feeds normal diet), every day 1 time, successive administration 4w.After last is administered, fasting overnight,
After next day weighs in, chloral hydrate anesthesia, put to death after postcava blood sampling.Take supernatant after Li Xin to survey
Biochemical indicator in serum.
2.2 Testing index:
(1) general status is observed, and records body weight weekly.
(2) each group rat blood serum lipid index: orbital venous plexus takes blood every two weeks, separation Virus monitory:
T-CHOL (TC), triglyceride (TG), high density lipoprotein (HDL-C), low density lipoprotein, LDL
(LDL-C)。
2.3 result
2.3.1 on the impact of TC, TG, HDL-C, LDL-C in serum
Iipid data in rat blood serum after table 3. modeling success even group-division
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model control group: p is equal
More than 0.05.
Table 4. is each after being administered 4W organizes Iipid data in rat blood serum
Note: compare with Normal group:#P ＜ 0.05,##P ＜ 0.01；Compare with model group: * p ＜ 0.05,
* p ＜ 0.01
From table 3, compare with Normal group, after model control group feeds high lipid food 4W, rat
Serum TC, LDL-C significantly raise (p ＜ 0.01), TG significantly raised (p ＜ 0.05), show hyperlipemia
Disease rat model modeling success.4 groups uniformly it are divided into according to blood lipid level.
From table 4, after being administered 4W, comparing with model control group, S1-S6 group can reduce in serum
TC, TG, LDL-C level (p ＜ 0.05 or p ＜ 0.01).
3. conclusion: S1-S6 has an obvious effect for reducing blood fat to Hyperlipemia model rat, and S1-S6
Compositions creates significant synergy in terms of blood fat reducing.
Experimental example 3: blood pressure lowering is tested
1, material and method
1.1 medicines and reagent: sample prepared by embodiment 1-6 and comparative example 1-3, be respectively designated as S1,
S2, S3, S4, S5, S6, and D1, D2, D3；The sodium chloride injection (normal saline) of 0.9%,
Specification: 250ml/ bottle, Kelun Pharm Ind Co., Ltd., Sichuan, lot number: C13102005-1；Distilled water,
Picric acid, etc..
1.2 instrument DKB-501A type super constant temperature water tanks, reliable test Instrument Ltd. for Shanghai is gloomy
Product；Constant Temp. Oven, for Changsha medical apparatus and instruments factory product；Powlab/4sp ML125 type without
Wound pressure measuring system (ML125/R NIBP, MLT1199BPTrans-ducer/Cable Kit), Australia is big
Leah Ai De Instrument Ltd. product；MP120-1 electronic balance, for Shanghai Second Balance Factory
Product.
1.3 laboratory animal SPF level SHR rats, body weight 190～230g, male, logical by Beijing dimension
Li Hua laboratory animal Technology Co., Ltd. provides, the quality certification number: SCXK (capital) 2012-0001.Animal in
SPF level barrier level Animal House is raised, and animal use credit number is: SYXK (Guangdong) 2012-0081,
SPF level WISTAR male rat, Beijing Vital River Experimental Animals Technology Co., Ltd. provides, real
Testing animal productiong credit number is: SCXK (capital) 2012-0001.
1.4 dosage arrange adult's plan dosage and are 3.0g/60kg BW days, and human body 10 times amount is rat
Dosage, dosage is with crude drug gauge.
1.5 statistical analysis use SPSS17.0 statistical software to carry out data process, and parameter mean ±
Standard deviation (x ± s) represents, comparing between group and use ANOVA variance analysis test, p ＜ 0.05 is for there being statistics
Learn difference.
2. method and result
10 groups are divided at random, often group 10 by male for 9-10 week old spontaneous hypertensive rat (SHR),
I.e. hypertension model matched group (giving distilled water), S1 group, S2 group, S3 group, S4 group, S5 group,
S6 group, D1 group, D2 group and D3 group.Separately take normal WISTAR rat 10 for Normal group
(giving distilled water).Each treated animal gavage respectively gives various dose drug, every day 1 time, is administered 4 altogether
Week.Within 4 weeks, rat tail artery blood is detected with noinvasive arteria caudalis pressure measuring system before being administered and after being administered
Pressure value (shrinks pressure, SAP, mmHg).
Noinvasive tail sleeve method (NIBP): rat is put into rat fixator, exposes rat-tail.Take with infrared
Warmer, temperature is set to 38 DEG C, and after irradiating heating rat-tail about 10min, rat-tail deliquescing, rat-tail is moved
Arteries and veins is fully expanded.Be passed through pressurizeing tail sleeve and being fixed on the root of rat-tail, make rat tail artery with
PowerlabML125/R noinvasive arteria caudalis blood pressure determination is analyzed the pulse transducer of system and is in close contact, with
Time observation system pulse wave, can start when stable pulse wave occurs to measure blood pressure.Treat that animal is pacified
After quiet, select 90～420BPM (rat pressurization shelves) to tail sleeve inflating pressure, it is seen that pulse wave gradually subtracts
Little to disappearing, then tail sleeve starts venting, and Mus set pressure reduces, and when pressure is equal to when shrinking pressure, starts
Pulse wave occur, the pressure value of this point is rat-tail and shrinks pressure.Repeated measure 3 times, averages.Meter
Calculating voltage drop value (drop-out value of blood pressure), before after administration, SAP deducts administration, SAP obtains.The results are shown in Table 5:
The impact to SHR rat blood pressure (SAP, mmHg) of table 5 sample
Note: compare with Normal group: # is P ＜ 0.01；Compare with model control group: * is P ＜ 0.05.
Result shows, compares with Normal group, and model control group rat blood pressure significantly raises, it is seen that from
The success of Essential hypertension rat model.With model control group, S1-S6 group can significantly reduce at administration 4W
The blood pressure (P ＜ 0.05) of SHR rat.
3. conclusion: S1-S6 sample has significant hypotensive activity, and the compositions of S1-S6 is at blood pressure lowering
Aspect creates significant synergism.
Present invention merely illustrates some claimed specific embodiments, one of them or
Technical characteristic described in more technical schemes can be with arbitrary one or more technical scheme phases
Combination, these are combined and the technical scheme that obtains also in the application protection domain, just as these are through group
As the technical scheme closed and obtain specifically is recorded in the disclosure of invention.
Claims (16)
1. a health composition, it comprises Cortex Mori and Pericarpium Citri Reticulatae.
Health composition the most according to claim 1, the wherein weight hundred of Cortex Mori and Pericarpium Citri Reticulatae
Proportion by subtraction is 1-99%: 1-99%.
Health composition the most according to claim 1 and 2, wherein Cortex Mori and the weight of Pericarpium Citri Reticulatae
Amount percentage ratio is 20-80%: 20-80%.
4. according to the health composition described in any one of claim 1-3, wherein Cortex Mori and Pericarpium Citri Reticulatae
Percentage by weight is 30-70%: 30-70%.
5. according to the health composition described in any one of claim 1-4, wherein Cortex Mori and Pericarpium Citri Reticulatae
Percentage by weight is 40-60%: 40-60%.
6. according to the health composition described in any one of claim 1-5, wherein said health composition
In also comprise the one in Rhizoma Polygonati Odorati, Rhizoma Dioscoreae, Radix Puerariae, Poria, leaf of Cyclocarya paliurus Iljinskaja or its combination in any, institute
State Cortex Mori, Pericarpium Citri Reticulatae and the one in Rhizoma Polygonati Odorati, Rhizoma Dioscoreae, Radix Puerariae, Poria, leaf of Cyclocarya paliurus Iljinskaja or it is any
The percentage by weight of combination is 1-98%: 1-98%: 1-98%.
Health composition the most according to claim 6, wherein Cortex Mori, Pericarpium Citri Reticulatae and Rhizoma Polygonati Odorati,
The percentage by weight of a kind of or its combination in any in Rhizoma Dioscoreae, Radix Puerariae, Poria, leaf of Cyclocarya paliurus Iljinskaja is
10-80%: 10-80%: 10-80%.
8., according to the health composition described in claim 6 or 7, wherein Cortex Mori, Pericarpium Citri Reticulatae are with beautiful
The percentage by weight of a kind of or its combination in any in bamboo, Rhizoma Dioscoreae, Radix Puerariae, Poria, leaf of Cyclocarya paliurus Iljinskaja is
20-60%: 20-60%: 20-60%.
9. according to the health composition described in any one of claim 1-8, wherein said health composition
In also comprise the one in Fructus Lycii, Radix Ginseng, Herba Dendrobii, Radix Angelicae Sinensis, Radix Rhodiolae Chinese medicine of the five flavours or it is any
Combination, the weight that one of described Chinese medicine of the five flavours or its combination in any are shared in health composition of the present invention
Percentage ratio is 10-40%.
Health composition the most according to claim 9, one of wherein said Chinese medicine of the five flavours or its
Combination in any accounts for 20-30% in health composition of the present invention.
11. according to the health composition described in claim 9 or 10, wherein said Chinese medicine of the five flavours it
One or its combination in any in health composition of the present invention, account for 25%.
12. according to the health composition described in any one of claim 1-11, it is characterised in that described
In compositions also comprise choosing free Rhizoma Polygonati, Thallus Laminariae (Thallus Eckloniae), Fructus Mume, Radix Notoginseng, Fructus Ligustri Lucidi, Fructus Corni, Rhizoma Chuanxiong,
Rhizoma Atractylodis, Radix Scrophulariae, Radix Rehmanniae, the Radix Paeoniae Alba, Radix Panacis Quinquefolii, Aloe, Fructus Schisandrae Chinensis, Radix Ophiopogonis, Radix et Rhizoma Rhei (processed),
The Rhizoma Anemarrhenae, Fructus Tribuli, Folium Ginkgo, the Radix Astragali, Herb Gynostemmae Pentaphylli, Fructus Momordicae charantiae, Radix Et Rhizoma Fagopyri Tatarici, Fructus Cucurbitae moschatae, Rhizoma amorphophalli, Herba Apii graveolentis,
One or more of in the group that Stigma Maydis, Tremella, Hericium erinaceus (Bull. Ex Fr.) Pers. and Bulbus Allii are formed.
Health composition described in 13. any one of claim 1-12 is at preparation treatment hyperglycemia, high blood
Application in pressure or hyperlipidemia health composition.
The pharmaceutical preparation of 14. 1 kinds of health compositions comprised described in any one of claim 1-12, its
Middle described health composition and pharmaceutically acceptable adjuvant are prepared as oral formulations.
15. pharmaceutical preparatioies according to claim 14, wherein said oral formulations be tablet,
Capsule, granule, powder, effervescent or bagged steeping drug.
16. according to the pharmaceutical preparation described in claims 14 or 15, wherein said pharmaceutically acceptable
Adjuvant fine selected from pregelatinized Starch, beta-schardinger dextrin-, carbomer, microcrystalline Cellulose, hydroxypropyl methyl
Dimension element, low-substituted hydroxypropyl cellulose, Polyethylene Glycol (PEG), sodium carboxymethyl cellulose, methyl
Cellulose, ethyl cellulose, mannitol, cross-linking sodium carboxymethyl cellulose, lactose, polyvinyl pyrrole
Alkanone (PVP), magnesium stearate, Pulvis Talci, micropowder silica gel, aspartame, sodium bicarbonate, carbon
Acid sodium in one or more of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510214672.7A CN106177054A (en) | 2015-04-29 | 2015-04-29 | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510214672.7A CN106177054A (en) | 2015-04-29 | 2015-04-29 | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106177054A true CN106177054A (en) | 2016-12-07 |
Family
ID=57457639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510214672.7A Withdrawn CN106177054A (en) | 2015-04-29 | 2015-04-29 | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106177054A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107343656A (en) * | 2017-06-08 | 2017-11-14 | 张挺 | A kind of health composition |
| CN108126038A (en) * | 2018-03-05 | 2018-06-08 | 苏州先蚕丝绸有限公司 | A kind of mulberry bark extract with lower hyperlipidemia, hypertension, hyperglycemia activity and preparation method thereof |
| CN111658709A (en) * | 2019-03-07 | 2020-09-15 | 江明康 | Traditional Chinese medicine composition with function of treating hypertension and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109336A (en) * | 1994-03-30 | 1995-10-04 | 李永丰 | Traditional Chinese medicinal liquor and its making-up method |
| CN1194117A (en) * | 1997-03-21 | 1998-09-30 | 王凯 | Health care drink and its producing method |
| CN102068625A (en) * | 2010-12-30 | 2011-05-25 | 蚌埠丰原涂山制药有限公司 | Traditional Chinese medicinal composition for reducing blood sugar and blood pressure and preparation method thereof |
| CN103749822A (en) * | 2013-12-31 | 2014-04-30 | 青岛恒波仪器有限公司 | Fructus ligustri lucidi health-care tea for lowering blood pressure and lipid and preparation method thereof |
-
2015
- 2015-04-29 CN CN201510214672.7A patent/CN106177054A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109336A (en) * | 1994-03-30 | 1995-10-04 | 李永丰 | Traditional Chinese medicinal liquor and its making-up method |
| CN1194117A (en) * | 1997-03-21 | 1998-09-30 | 王凯 | Health care drink and its producing method |
| CN102068625A (en) * | 2010-12-30 | 2011-05-25 | 蚌埠丰原涂山制药有限公司 | Traditional Chinese medicinal composition for reducing blood sugar and blood pressure and preparation method thereof |
| CN103749822A (en) * | 2013-12-31 | 2014-04-30 | 青岛恒波仪器有限公司 | Fructus ligustri lucidi health-care tea for lowering blood pressure and lipid and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107343656A (en) * | 2017-06-08 | 2017-11-14 | 张挺 | A kind of health composition |
| CN108126038A (en) * | 2018-03-05 | 2018-06-08 | 苏州先蚕丝绸有限公司 | A kind of mulberry bark extract with lower hyperlipidemia, hypertension, hyperglycemia activity and preparation method thereof |
| CN111658709A (en) * | 2019-03-07 | 2020-09-15 | 江明康 | Traditional Chinese medicine composition with function of treating hypertension and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104435775A (en) | Chinese medicinal health-care spirit and preparation method thereof | |
| CN102784363B (en) | Traditional Chinese medicine composition for treating pancreatic cancer and preparation method thereof | |
| CN106176918A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Radix Puerariae | |
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN104208302A (en) | Fructus rosae laevigatae healthy oral solution for reducing blood fat and preparation method thereof | |
| CN105749179A (en) | Traditional Chinese medicine composition for treating metabolic syndrome | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN105031517A (en) | Dendrobium officinale healthcare tea capable of reducing blood fat, blood sugar, and blood pressure and preparation method thereof | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN104206594A (en) | Herba Taxilli health-care tea capable of lowering blood pressure and blood lipid and preparation method thereof | |
| CN106176953A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori | |
| CN103223111A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN102885975B (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN106177434A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Rhizoma Polygonati Odorati | |
| CN106176952A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja and Folium Ilicis | |
| CN106177433A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Radix Puerariae and Rhizoma Polygonati Odorati | |
| CN106177054A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae | |
| CN106173605A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Herba Dendrobii | |
| CN103749819A (en) | Cornus officinalis sieb health-care tea capable of lowering blood sugar and lowering lipid and preparation method of tea | |
| CN106177479A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Rhizoma Polygonati Odorati | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN105343593A (en) | Spica prunellae health oral liquid capable of decreasing blood pressure and blood lipid as well as preparation method of spica prunellae health oral liquid | |
| CN105056103A (en) | Steamed buns with assistant effect of reducing blood fat and cholesterol and processing method of steamed buns |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161207 |